[3-Year experience of use of cefepime (Maxipime) for the treatment of hospital infections in a specialized surgical hospital].
Microbiological and clinical monitoring for 3 years (from 2001 to 2003) confirmed high clinical and microbiological efficacy of cefepime (Maxipime, Bristol-Myers-Squibb) in the treatment of infectious complications in patients with solid tumors in an oncologic hospital. It should be noted, however, that high efficacy of cefepime and wide ranges of the indications to its use do not allow to consider it as an agent for the treatment of all possible complications in such patients. The drug is not active against enterococci, not always clinically sufficiently effective in the treatment of Pseudomonas aeruginosa infections, it is impossible to use cefepime in monotherapy of suspected anaerobic infections. Therefore, widespread uncontrolled use of cefepime should be prohibited. It should be prescribed strictly by the indications with the account of the pathogen susceptibility, the infection severity and the recommended doses and regimens. The use of cefepime is undoubtedly valid when other antimicrobials fail or when empirical antimicrobial therapy of severe cases is required, including those under intensive care.
Mitrokhin
S D
SD
Municipal Clinical Oncologic Hospital No. 62, Moscow.
Avilova
N D
ND
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000077723:Cefepime; D002511:Cephalosporins / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D006090:Gram-Negative Bacteria / Q000145:classification / Q000302:isolation & purification; D006801:Humans; D009369:Neoplasms / Q000150:complications
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000077723:Cefepime